Evaluation the anti-inflammatory effects of curcumin in the treatment of patients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; Corona virus infection, unspecified; U07.1

• Registration Number: IRCT20200519047510N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Confirmed COVID-19 infection
Conscious consent to participate in the study

Exclusion Criteria

Pregnancy and lactation
Long-term use of immunosuppressive drugs
Use of nutritional supplements
Dissatisfaction to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gene expression of inflammatory cytokines in peripheral blood mono-nuclear cells of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: real time-PCR.;Serum levels of inflammatory cytokines of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: ELISA technique.;Clinical symptoms of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Examination by a specialist.;Laboratory findings of patients receiving nanocurcumin and the control group. Timepoint: Before and after the intervention (0 and 7 days). Method of measurement: Laboratory findings in the Patient file.